News coverage about Vertex Pharmaceuticals (NASDAQ:VRTX) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the pharmaceutical company an impact score of 45.3707996414251 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
A number of analysts have weighed in on the stock. Barclays raised their price objective on shares of Vertex Pharmaceuticals from $180.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. HC Wainwright reiterated a “hold” rating and issued a $103.00 price target on shares of Vertex Pharmaceuticals in a research note on Thursday, February 1st. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Sunday, January 21st. Robert W. Baird reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Friday, October 27th. Finally, Citigroup reiterated a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, February 1st. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $180.11.
Shares of Vertex Pharmaceuticals (NASDAQ VRTX) opened at $152.01 on Tuesday. Vertex Pharmaceuticals has a 1 year low of $84.39 and a 1 year high of $174.96. The firm has a market cap of $38,737.58, a price-to-earnings ratio of 146.16, a P/E/G ratio of 2.23 and a beta of 1.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.79 and a quick ratio of 4.58.
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.08. The firm had revenue of $651.63 million during the quarter, compared to analyst estimates of $592.49 million. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The business’s revenue was up 42.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.35 earnings per share. analysts forecast that Vertex Pharmaceuticals will post 1.63 EPS for the current fiscal year.
Vertex Pharmaceuticals announced that its Board of Directors has initiated a share buyback plan on Wednesday, January 31st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the pharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.
In related news, CFO Thomas Graney sold 777 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $149.95, for a total value of $116,511.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Stuart A. Arbuckle sold 221 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $147.29, for a total transaction of $32,551.09. The disclosure for this sale can be found here. Insiders have sold 403,165 shares of company stock valued at $62,154,183 over the last three months. Insiders own 1.80% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Vertex Pharmaceuticals (VRTX) Share Price” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/13/vertex-pharmaceuticals-vrtx-earning-somewhat-favorable-press-coverage-accern-reports.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.